Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Boehringer Ingelheim GmbH : Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/23/2012 | 11:04am CEST

Ingelheim, Germany and Cambridge, UK - 23 July 2012 Today, Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics' FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, "by acquiring the Funxional Therapeutics programme, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD."

David Grainger, Founder and CSO of Funxional Therapeutics commented: "We are very pleased that the future development of FX125L and the somatotaxin programme will be now driven forward by Boehringer Ingelheim. They are a very impressive organisation and their people have the necessary knowledge, skills and experience to successfully develop FX125L."

Funxional Therapeutics was founded by David Grainger with initial investment from Index Ventures and Novo A/S in 2006. Ventech led the Series B financing. Index Ventures' partner and Chairman of the board, Michele Ollier said: "This acquisition is further validation of Index's business model and we congratulate the team who have delivered first class science and developed a very exciting molecule. They have done an extraordinary job of building this company."

Notes for Editors

About Somatotaxins
The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. FXT's portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery.

About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT's focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases. Funxional Therapeutics was founded in 2005 based on intellectual property developed by Dr David Grainger and his colleagues at Cambridge University, in collaboration with Ipsen, a global specialty-driven pharmaceutical company targeting debilitating diseases in neurology, endocrinology, uro-oncology and hemophilia. Index Ventures and Novo A/S provided first round funding to initiate research and development activities. Further funding was led by Ventech.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
10:46p FAIR ISAAC CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
10:46p BROWER PIVEN ENCOURAGES INVESTORS WHO HAVE LOSSES IN EXCESS OF $100,000 FROM INVESTMENT IN ZOOMPASS HOLDINGS, INC. (OTC MKTS : ZPAS) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
10:45p PEBBLEBROOK HOTEL TRUST : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
10:45p CASTLIGHT HEALTH, INC. (NYSE : CSLT) Files An 8-K Submission of Matters to a Vote of Security Holders
10:45p CYPRESS SEMICONDUCTOR CORP /DE/ : Submission of Matters to a Vote of Security Holders (form 8-K)
10:45p REALBIZ MEDIA GROUP, INC. (OTCMKTS : RBIZ) Files An 8-K Entry into a Material Definitive Agreement
10:45p KINROSS GOLD : to announce Q2 financial results on August 2, 2017
10:45p IIROC Trade Halt - Crosswinds Holdings Inc.
10:45p AKARI THERAPEUTICS PLC (ADR) : Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm
10:44p MY NEW FAVORITE THING : Superficial radiation therapy
Latest news
Advertisement
Hot News 
13.77%BANCA INTERMOBILIARE DI INVEST E GEST : Italy's BIM head confident the unit can be sold fast after Veneto Banca liquidation
3.52%INTESA SANPAOLO : Italian banks rally after taxpayer-funded Veneto deal
2.90%Third Point leans on Dutch turnaround expert for Nestle push
-1.35%Kinnevik appoints Georgi Ganev as CEO
0.31%CROWN RESORTS : China jails Crown Resorts staff over gambling crimes
Most Read News
05:01a INSTINET : and Virtu Financial launch liquidity streaming relationship
04:38p WALL STREET STOCK EXCHANGE : S&P 500, Dow edge up; tech weighs on Nasdaq
11:48a HYTERA COMMUNICATIONS : China, Canada vow not to conduct cyber attacks on private sector
03:27p U.S. activist presses for 'bold action' at Nestle
07:13a MIKHAIL FRIDMAN : Fridman's L1 Retail to buy Holland & Barrett for $2.3 billion
Most recommended articles
04:44pDJSenate Health Bill Raises Uninsured by 22 million in 2026 Compared to ACA, the CBO Says
04:39p Amtrak names former Delta executive as next CEO
04:38p WALL STREET STOCK EXCHANGE : S&P 500, Dow edge up; tech weighs on Nasdaq
04:37p STUART CHAMBERS : UK's Travis Perkins to name ex-ARM chairman Stuart Chambers as new chair - Sky News
04:30pDJWheat Falls as Rain Improves Outlooks; Corn and Soybeans Steady